Study of a Novel Antipsychotic ITI-007 in Schizophrenia

NCT01499563 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

335

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: ITI-007
DRUG: Placebo
DRUG: Risperidone

Sponsor

Intra-Cellular Therapies, Inc.